Background {#Sec1}
==========

The pipeline of drugs for rare diseases (DRD) has been increasing as biochemical research has shifted focus from blockbusters to 'niche' drugs \[[@CR1]\]. While all rare diseases, by definition, affect relatively small populations, the exact number of patients affected and the extent of the severity of the condition used to define a rare disease is a matter of continuous debate \[[@CR2]\]. The regulator in Canada, Health Canada, is yet to officially adopt a definition of a rare disease, although in a 2014 press release, Health Canada defined a rare disease as a "life-threatening, seriously debilitating, or serious chronic condition that only affects a very small number of patients (typically less than 5 in 10,000 persons)" \[[@CR3]\].

The Canadian Agency for Drugs and Technologies in Health (CADTH) is a publicly funded Canadian health technology assessment (HTA) organization that evaluates drugs for reimbursement purposes through its Common Drug Review (CDR) and pan-Canadian Oncology Drug Review \[pCODR\] processes \[[@CR4]\]. Through its advisory body, the Canadian Drug Expert Committee (CDEC), CADTH offers non-binding reimbursement recommendations to all public drug plans in Canada except for those in Quebec, which has a separate review process. Overall, CDEC provides reimbursement recommendations under three themes: List, List with clinical criteria or conditions, and do not list. It has been reported that participating drug plans adhere to these recommendations in more than 90% of formulary listings \[[@CR4]\]. In 2012, CADTH received a formal mandate from its federal, provincial, and territorial (F/P/T) funders to review DRDs \[[@CR5]\]. Prior to 2012, there was no formal distinction given for DRDs and CADTH evaluated such drugs under the same process as non-DRDs. After a formal stakeholder consultation, CADTH decided to keep the evaluation of DRDs under an enhanced CDR process, with more emphasis on engagement of specialists, patient input, and offering opportunities for manufacturers to engage in dialogue with CADTH earlier in the pre-submission phase \[[@CR6]\]. As such, CADTH has no formal definition that would make a distinction between DRDs and non-DRDs.

This report provides a summary of key characteristics for all DRD submissions that have been filed for review through the CDR process, an analysis of the volume and frequency of DRD submissions, and a detailed examination of the reimbursement recommendations and reasons for reimbursement recommendation that have been issued for DRDs. This will allow us to draw a bigger picture of the fast evolving landscape of DRDs, explore the characters of DRDs CDR submissions, and to gain insight into the evidence base that supports HTA process for DRDs.

Methods {#Sec2}
=======

On February 3, 2016, CDR reimbursement recommendation reports published on the CADTH website ([www.cadth.ca](http://www.cadth.ca)) were screened for inclusion in this review. A drug was included if it was reviewed for use in the management of a disease with a prevalence or birth prevalence of less than 50 in 100,000 people. This definition of rare diseases is in line with most international jurisdictions \[[@CR2]\]. Two independent reviewers (G.J. and W.A.) screened the retrieved reports. First-level screening excluded CDR reports with indications for diseases that are not rare. Second-level screening required the reviewer to provide the prevalence of the disease before a decision to exclude or include was made. Discrepancy between the two reviewers was resolved through arbitration of a third independent reviewer (T.R.). One reviewer (G.J.) extracted the following data from the published CDR reports: CADTH project ID, project status, date of submission, type of submission, disease under review, prevalence of disease under review, Health Canada indication, manufacturer name, drug brand name, drug non-proprietary name, number of studies considered within the CDR review, type of studies considered in each submission, comparisons used in the studies, size of the largest study, highest evidence level (with no double counting allowed), per patient annual treatment cost, cost per quality-adjusted life year (QALY), reimbursement recommendation, and reason(s) for a negative reimbursement recommendation. If prevalence data were not reported in the CDR report, we sought a Canadian published estimate in the literature, if such estimate could not be found, then the prevalence point estimates was informed from the Orphanet report series \[[@CR7]\]. Full data-set is available from the corresponding author upon reasonable request.

We categorized reimbursement recommendations as either "List", "Do Not List", or "List with Conditions/Criteria". A reimbursement recommendation of "do not list at the submitted price" was classified as "Do Not List". We thematically explored reasons for a negative reimbursement recommendation (i.e., a "Do Not List") based on the most prominent reason stated within the recommendation report, and each reason was categorized as one of the following:Insufficient evidence: in cases where the committee found the evidence to be of poor quality with a high degree of statistical uncertainty and methodological limitationsLack of clinical effectiveness: in cases where the committee could not determine the actual clinical value to be observed in practice due to a lack of (a) relevant clinical outcomes, (b) knowledge of what constituted a minimal clinically important difference (MCID), or (c) the use of outcomes tha﻿t are not validated. Usually, in this category, high-quality studies would have been considered, and the drug would have potentially shown statistical significance in possible surrogate outcomesLack of cost-effectiveness/high cost: in cases where the committee determined the treatment price to be contextually unacceptableMultiple reasons: in cases where more than one of the aforementioned reasons was applicable

Due to the implementation of a revised reimbursement recommendation framework at the CADTH CDR in November 2012 \[[@CR8]\], a subgroup analysis of CDEC reimbursement recommendations that were issued after October 2012 were further analyzed separately. The accuracy of the extracted data was verified by a second reviewer (T.R.).

We calculated descriptive statistics of various parameters, including the average, standard deviation (SD), 95% confidence interval (95%CI), median, and range of continuous variables. Categorical variables are presented as percentages.

Results {#Sec3}
=======

Of 434 records retrieved on February 3, 2016, we identified 63 submissions for DRDs. Of these 63 submissions, four were ongoing at the time of the search, and the reimbursement recommendations and clinical report were not available. Therefore, there was no information available for these DRDs regarding the studies included in the submission, the price, and reimbursement recommendations. Assessment of the number of DRD submissions made to the CADTH CDR revealed two distinct, contrasting periods: the first period was between 2004 and 2012, within which the number of submissions was generally between 4 and 5 per year, and ranged from a minimum of 1 submission in 2005 to a maximum of 5 submissions in each of the years 2004, 2009, 2010, and 2012; the second period was between 2013 and 2015, which was distinct from the preceding period in that the number of submissions increased, up to 10, 9, and 8 submissions for the years 2013, 2014, and 2015, respectively. Figure [1](#Fig1){ref-type="fig"} illustrates the temporal trend in the volume of DRD submissions.Fig. 1Number of CDR submissions for drugs for rare diseases per year for the period 2004 to 2015. Numbers above columns indicate the number of submissions

Table [1](#Tab1){ref-type="table"} lists the date of each submission, along with the drug name, manufacturer name, the rare disease for which the drug is indicated, the prevalence of the disease, and the CDEC reimbursement recommendation. Examination of these data revealed that Pfizer Canada made more DRD submissions than any other pharmaceutical manufacturer (a total of six submissions), followed by Genzyme Canada (five submissions), and Alexion, Hoffman-La Roche, and Novartis (four submissions each).Table 1CDR for rare diseasesDate of submissionDrug brand nameDrug non-proprietary nameManufacturerPharmacological categoryDiseasePrevelance of disease (/100,000)CDEC reimbursement recommendation19/02/2004Replagalagalsidase alfaTranskaryotic Therapies Inc.Biologic/Enzyme replacement therapyFabry Disease0.22^a^Do not list24/02/2004Fabrazymeagalsidase betaGenzyme Canada Inc.Biologic/Enzyme replacement therapyFabry Disease0.22^a^Do not list14/07/2004RemodulinTreprostinil sodiumNorthern Theraputics Inc.Chemical/Vasodilating AgentsPulmonary arterial hypertension3.3^a^Do not list24/11/2004ZavescamiglustatActelion Pharmaceuticals Canada Inc.Chemical/Substrate reduction therapy, Enzyme Inhibitor; Glucosylceramide Synthase InhibitorGaucher disease1^a^Do not list10/12/2004Fabrazymeagalsidase betaGenzyme Canada Inc.Biologic/Enzyme replacement therapyFabry Disease0.22^a^Do not list03/02/2005AldurazymelaronidaseGenzyme Canada Inc.Biologic/Enzyme replacement therapyMucopolysaccharidosis I8^a^Do not list25/01/2006SomavertpegvisomantPfizer Canada Inc.Biologic/Growth hormone receptor antagonistAcromegaly5.5^a^Do not list24/02/2006RemodulinTreprostinil sodiumNorthern Theraputics Inc.Chemical/Vasodilating AgentsPulmonary arterial hypertension3.3^a^List with criteria/condition20/07/2006SutentsunitinibPfizer Canada Inc.Chemical/Antineoplastic Agent, Tyrosine Kinase Inhibitor; Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) InhibitorGastrointestinal stromal tumour13^a^List with clinical criteria and/or conditions10/10/2006MyozymealglucosidaseGenzyme Canada Inc.Biologic/Enzyme replacement therapyGlycogen storage disease type II0.8^a^List with clinical criteria and/or conditions20/02/2007Somatulinelanreotide acetateIpsen LimitedChemical/Somatostatin AnalogAcromegaly5.5^a^List in a similar manner to other drugs in class22/06/2007ThelinSitaxsentan sodiumEncysive Canada Inc.Chemical/Endothelin receptor antagonistPulmonary arterial hypertension3.3^a^Do not list13/07/2007ElapraseidursulfaseShire Human Genetic Therapies (Canada) Inc.Biologic/Enzyme replacement therapyMucopolysarccharidosis II6.7^a^Do not list29/08/2007Xyremsodium oxybateValeant Canada Ltd.Chemical/Central Nervous System DepressantNarcolepsy25^a^Withdrawn05/05/2008ThelinSitaxsentan sodiumEncysive Canada Inc.Chemical/Endothelin receptor antagonistPulmonary arterial hypertension3.3^a^Do not list09/07/2008Xyremsodium oxybateValeant Canada Ltd.Chemical/Central Nervous System DepressantNarcolepsy25^a^Do not list09/07/2008VolibrisAmbrisentanGlaxoSmithKlineChemical/Endothelin receptor antagonistPulmonary arterial hypertension3.3^a^List with clinical criteria and/or conditions29/08/2008OrenciaAbataceptBristol-Myers Squibb CanadaBiologic/Selective T Cell Costimulation ModulatorJuvenile idiopathic arthritis (JIA)44.7^b^List with criteria/condition12/06/2009Omnitropesomatropin (rDNA origin)Sandoz Canada Inc.Biologic/Growth hormoneGrowth hormone deficiency in children and adults37^c^List in a similar manner to other drugs in class12/06/2009Xeominclostridium botulinum neurotoxin type A, free of complexing proteinsMerz Pharmaceuticals GmbHBiologic/Neuromuscular Blocker Agent, Toxin; Ophthalmic Agent, ToxinBlepharospasm16.43^d^List in a similar manner to other drugs in class12/06/2009Xeominclostridium botulinum neurotoxin type A, free of complexing proteinsMerz Pharmaceuticals GmbHBiologic/Neuromuscular Blocker Agent, Toxin; Ophthalmic Agent, ToxinCervical dystonia16.43^d^List in a similar manner to other drugs in class18/09/2009SoliriseculizumabAlexion Pharmaceuticals Inc.Biologic/Monoclonal Antibody; Monoclonal Antibody, Complement InhibitorParoxysmal nocturnal hemoglobinuria0.2^a^Do not list29/09/2009NplateRomiplostimAmgen Canada Inc.Biologic/Colony Stimulating Factor; Hematopoietic Agent; Thrombopoietic AgentImmune thrombocytopenic purpura25^a^Do not list05/02/2010AdcircaTadalafilEli Lilly Canada Inc.Chemical/Enzyme inhibitorPulmonary arterial hypertension3.3^a^List with criteria/condition07/07/2010IlariscanakinumabNovartis Pharmaceuticals Canada Inc.Biologic/Interleukin-1 Beta Inhibitor; Interleukin-1 Inhibitor; Monoclonal AntibodyCryopyrin-Associated Periodic Syndrome (CAPS)0.3^e^Do not list08/07/2010Kuvansapropterin dihydrochlorideBioMarin Pharmaceutical (Canada) Inc.Chemical/Enzyme Cofactor, activates residual PAH enzymePhenylketonuria10^a^Do not list28/10/2010Vprivvelaglucerase alfaShire Human Genetic Therapies (Canada) Inc.Biologic/Enzyme replacement therapyGaucher disease1^a^List with clinical criteria and/or conditions02/12/2010CaystonaztreonamGilead Sciences Canada Inc.Chemical/AntibioticCystic fibrosis7.4^a^List with clinical criteria and/or conditions26/04/2011RevoladeEltrombopag olamineGlaxoSmithKlineChemical/Colony Stimulating Factor; Hematopoietic Agent; Thrombopoietic AgentImmune thrombocytopenic purpura25^a^Do not list01/06/2011Kuvansapropterin dihydrochlorideBioMarin Pharmaceutical (Canada) Inc.Chemical/Enzyme Cofactor, activates residual PAH enzymePhenylketonuria10^a^NR20/09/2011BanzelRufinamideEisai LimitedChemical/Anticonvulsant, Triazole DerivativeLennox-Gastaut Syndrome15^a^List with clinical criteria and/or conditions24/01/2012Mozobilplerixafor injectionGenzyme Canada Inc.Chemical/Hematopoietic Agent; Hematopoietic Stem Cell MobilizerNon-Hodgkin's lymphoma and multiple myeloma11.9^a^Do not list30/01/2012ActemratocilizumabHoffmann-La Roche Ltd.Biologic/Antirheumatic, Disease Modifying; Interleukin-6 Receptor AntagonistJuvenile idiopathic arthritis44.7^b^List24/02/2012RituxanRituximabHoffmann-La Roche Ltd.Biologic/Antineoplastic Agent, Anti-CD20; Antineoplastic Agent, Monoclonal Antibody; Antirheumatic, Miscellaneous; Immunosuppressant Agent; Monoclonal AntibodyGranulomatosis with Polyangiitis9^a^List with clinical criteria and/or conditions27/09/2012Kalydecoivacaftor tabletsVertex Pharmaceuticals (Canada) Inc.Chemical/Cystic Fibrosis Transmembrane Conductance Regulator PotentiatorCystic fibrosis7.4^a^List with criteria/condition05/10/2012EsbrietpirfenidoneInterMune Canada Inc.Chemical/Anti-inflammatory Agent; Antifibrotic AgentIdiopathic pulmonary fibrosis (IPF)42.7^f^Do not list07/01/2013SoliriseculizumabAlexion Pharmaceuticals Inc.Biologic/Monoclonal Antibody; Monoclonal Antibody, Complement InhibitorAtypical Hemolytic Uremic Syndrome0.85^a^Do not list04/02/2013HumiraadalimumabAbbVie CorporationBiologic/Antirheumatic, Disease Modifying; Gastrointestinal Agent, Miscellaneous; Monoclonal Antibody; Tumor Necrosis Factor (TNF) Blocking AgentJuvenile idiopathic arthritis (JIA)44.7^b^List with clinical criteria and/or conditions08/03/2013AfinitorEverolimusNovartis Pharmaceuticals Canada Inc.Chemical/Antineoplastic Agent, mTOR Kinase Inhibitor; Immunosuppressant Agent; mTOR Kinase InhibitorTuberous sclerosis8.8^a^Do not list27/05/2013Genotropin GHD-AsomatropinPfizer Canada Inc.Biologic/Growth HormoneGrowth hormone deficiency37^c^List with clinical criteria and/or conditions27/05/2013Genotropin GHD-PsomatropinPfizer Canada Inc.Biologic/Growth HormoneGrowth hormone deficiency37^c^List with clinical criteria and/or conditions27/05/2013Genotropin TSsomatropinPfizer Canada Inc.Biologic/Growth HormoneTurner syndrome50^g^List with criteria/condition06/06/2013JetreaocriplasminAlcon Canada Inc.Biologic/Ophthalmic Agent; VitreolyticVitreomacular adhesion40^h^List with criteria/condition29/07/2013ActemratocilizumabHoffmann-La Roche Ltd.Biologic/Antirheumatic, Disease Modifying; Interleukin-6 Receptor AntagonistJuvenile idiopathic arthritis (JIA)44.7^b^List with criteria/condition30/09/2013AdempasRicoiguatBayer Inc.Chemical/Soluble Guanylate Cyclase (sGC) StimulatorPulmonary arterial hypertension3.3^a^List with criteria/condition16/12/2013OpsumitMacitentanActelion Pharmaceuticals Canada Inc.Chemical/Endothelin Receptor Antagonist; VasodilatorPulmonary arterial hypertension3.3^a^List with criteria/condition27/02/2014SigniforpasireotideNovartis Pharmaceuticals Canada Inc.Chemical/Somatostatin AnalogCushing\'s Disease4^a^Do not list04/03/2014FirazyricatibantShire Human Genetic Therapies (Canada) Inc.Chemical/Selective Bradykinin B2 Receptor AntagonistHereditary angioedema1^a^List with clinical criteria and/or conditions19/03/2014AfinitorEverolimusNovartis Pharmaceuticals Canada Inc.Chemical./Antineoplastic Agent, mTOR Kinase Inhibitor; Immunosuppressant Agent; mTOR Kinase InhibitorTuberous Sclerosis8.8^a^Do not list01/05/2014KalydecoivacaftorVertex Pharmaceuticals (Canada) Inc,Chemical/Cystic Fibrosis Transmembrane Conductance Regulator PotentiatorCystic fibrosis7.4^a^List with criteria/condition08/07/2014JuxtapidlomitapideAegerion Pharmaceuticals (Canada) Ltd.Chemical/Antilipemic Agent, Microsomal Triglyceride Transfer Protein (MTP) InhibitorHomozygous Familial Hypercholesterolemia0.6^i^Do not list05/08/2014Vimizimelosulfase alfaBioMarin Pharmaceutical (Canada) Inc.Biologic/Enzyme replacement therapyMucopolysaccharidosis IV0.3^j^Do not list29/08/2014EsbrietpirfenidoneHoffmann-La Roche Ltd.Chemical/Anti-inflammatory Agent; Antifibrotic AgentIdiopathic pulmonary fibrosis (IPF)42.7^f^List with criteria/condition15/09/2014ElelysoTaliglucerase alfaPfizer Canada Inc.Biologic/Enzyme replacement therapyGaucher disease1^a^Do not list30/10/2014DiacomitStiripentolBiocodexChemical/AnticonvulsantDravet Syndrome2.5^a^List with criteria/condition09/02/2015SoliriseculizumabAlexion Pharmaceuticals Inc.Biologic/Monoclonal Antibody; Monoclonal Antibody, Complement InhibitorAtypical Hemolytic Uremic Syndrome0.85^a^Do not list23/04/2015OfevNintedanibBoehringer Ingelheim (Canada) Ltd.Chemical/Tyrosine Kinase InhibitorIdiopathic pulmonary fibrosis (IPF)42.7^f^List with criteria/condition08/05/2015KalydecoIvacaftorVertex Pharmaceuticals (Canada) Inc.Chemical/Cystic Fibrosis Transmembrane Conductance Regulator PotentiatorCystic fibrosis7.4^a^List with criteria/condition25/06/2015AdempasRiociguatBayer Inc.Chemical/Soluble Guanylate Cyclase (sGC) StimulatorPulmonary arterial hypertension3.3^a^List with criteria/condition20/07/2015StrensiqAsfotase alfaAlexion Pharmaceuticals Inc.Biologic/Enzyme replacement therapyHypophophatasia1^k^Ongoing20/08/2015NaglazymeGalsulfaseBioMarin Pharmaceutical (Canada) Inc.Biologic/Enzyme replacement therapyMucopolysaccharidosis VI0.3^j^Ongoing24/11/2015IlariscanakinumabNovartis Pharmaceuticals Canada Inc.Biologic/Interleukin-1 Beta Inhibitor; Interleukin-1 Inhibitor; Monoclonal AntibodyJuvenile idiopathic arthritis44.7^b^Ongoing27/11/2015Orkambilumacaftor/ivacaftorVertex Pharmaceuticals (Canada) Inc.Chemical/CFTR combinationsCystic fibrosis7.4^a^OngoingSources of prevalence estimates^a^Orphanet Report Series - Prevalence of rare diseases: Bibliographic data - July 2015 - Number 2. <http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf>. Last accessed January, 2016^b^Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014 Mar;81(2):112--7. doi: 10.1016/j.jbspin.2013.09.003. Epub 2013 Nov 6^c^Stochholm K, Gravholt CH, Laursen T, Jorgensen JO, Laurberg P, Andersen M. Incidence of GH deficiency - a nationwide study. Eur J Endocrinol. 2006 Jul. 155(1):61-71^d^Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012 Dec;27(14):1789--96. doi: 10.1002/mds.25244. Epub 2012 Oct 31^e^Kümmerle-Deschner JB. \[Cryopyrin-associated periodic syndrome\] \[Article in German\]. Z Rheumatol. 2012 Apr;71(3):199--208. doi: 10.1007/s00393-011-0856-9^f^Ganesh Raghu, Derek Weycker, John Edelsberg, Williamson Z. Bradford, Gerry Oster. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med Vol 174. pp 810--816, 2006^g^Claus Højbjerg Gravholt, Kirstine Stochholm. The epidemiology of Turner syndrome. International Congress Series. Volume 1298, October 2006, Pages 139--145^h^Ocriplasmin (Jetrea) (125 mcg intravitreal injection) CADTH Common Drug Review Clinical Review Report. January 2014. Available <https://www.cadth.ca/sites/default/files/cdr/clinical/SR0337_Jetrea_CL_Report_e.pdf>^i^lomitapide (Juxtapid) (oral capsules) CADTH Common Drug Review Clinical Review Report. July 2015. Available <https://www.cadth.ca/sites/default/files/cdr/clinical/SR0386_Juxtapid_CL_Report_e.pdf>^j^Lowry, R.B., Applegarth, D.A., Toone, J.R. et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet (1990) 85: 389. doi:10.1007/BF00206770^k^Fraser D. Hypophosphatasia. Am J Med, 1957; 730--746

Of the 63 DRD submissions, approximately half (30 or 47.6%) were for drugs that were classified by Health Canada as biologics, with the remainder being small molecules. The average prevalence of diseases for which DRD submissions were reviewed at CDR was 14.0 patients per 100,000 people (SD: 16.0; 95%CI: 9.9 to 18.0; range: 0.2 to 50.0 per 100,000 people; median: 7.4 per 100,000 people). Figure [2](#Fig2){ref-type="fig"} presents the number of submissions by prevalence. Figure [2](#Fig2){ref-type="fig"} illustrates that more than half of all DRD submissions (61.9%) were for treatments for rare diseases with a prevalence of less than 10 patients per 100,000 people, with the remainder of the DRD submissions (38.1%) being for treatments for diseases with a prevalence between 10 and 50 patients per 100,000 people. This suggests that there is a tendency for DRD submissions to target relatively less prevalent rare diseases.Fig. 2Number of CDR submissions for drugs for rare diseases by indicated disease prevalence. Numbers above columns indicate the number of submissions

Of the 54 (85.7%) submissions in which the number of clinical studies considered by CDEC was reported, the average number of clinical studies per submission was 2.5 (SD: 2.0; 95%CI: 2.0 to 3.0), with a median of 2 and a range of 1 to 14 (Fig. [3](#Fig3){ref-type="fig"}). Of the 57 (90.5%) submissions for which information about the types of studies was available, 47 (74.6.7%) had at least one double-blind randomized clinical trial (RCT) as the highest level of evidence, 3 submissions (4.7%) had at least one open-label RCT as the highest level of evidence, and 7 (11.1%) had at least one non-controlled trial as highest level of evidence (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Number of CDR submissions for drugs for rare diseases by the number of clinical studies considered in each submission. Numbers above columns indicate the number of submissions Fig. 4Type of best evidence included in the CDR submissions of drugs for rare diseases. Numbers above columns indicate the number of submissions

The study size (i.e., number of study subjects) for clinical studies that were considered in the CDR review of DRD submissions was reported for 49 (77.8%) of the included submissions. The largest clinical study per submission ranged from 20 to 742 subjects, with a median of 122 subjects. The average size of the largest study within each submission was 171.9 (SD: 171.9; 95%CI: 140.1 to 238.8). Figure [5](#Fig5){ref-type="fig"} presents the number of submissions by the size of the largest included trial.Fig. 5Number of CDR submissions by the size of the largest clinical study considered in each submission. Numbers above columns indicate the number of submissions

Information regarding the annual treatment cost per patient was available for only 31 (49.2%) of the included DRD submissions. The reasons for not reporting the annual treatment cost included confidential pricing (15 submissions or 23.8%), an annual treatment cost not applicable to the indication under review (12 submissions or 19.0%), or ongoing or withdrawn submissions (5 submissions or 7.9%). The average annual treatment cost per patient for the 31 DRD submission for which cost information was available was \$215,632 (SD: 240,858.8; 95%CI: 127,283.9 to 303,979.3), with a median of \$104,890 with a minimum annual price of \$9,706 and a maximum annual price of \$940,084. Figure [6](#Fig6){ref-type="fig"} illustrates almost half of the DRD submissions (45.2%) were for treatments with a cost greater than \$200,000 per patient per year.Fig. 6Average annual treatment cost per patient of drugs for rare diseases

Analysis of the type of reimbursement recommendations issued since 2004 for DRD submissions revealed that a negative reimbursement recommendation was issued for 26 (44.8%) submissions, while one submission was withdrawn (1.7%); the remaining 31 submissions (53.5%) received positive reimbursement recommendations, of which 8.6% were to "list" and 44.8% were to "list with criteria/conditions" (Fig. [7](#Fig7){ref-type="fig"}). Not included in the previous analysis are four submissions that were ongoing at the time of data collection, as such no recommendation was available, and one submission was a request for advice that did not yield a published recommendation. Overall, reasons for a negative reimbursement recommendation included lack of clinical effectiveness (10 submissions or 38.5%), insufficient evidence (8 submissions or 30.8%), multiple reasons (6 submissions or 23.1%), and lack of cost-effectiveness/high cost (2 submissions or 7.7%) (Fig. [8](#Fig8){ref-type="fig"}). A subgroup analysis of reimbursement recommendations and reasons for a negative reimbursement recommendations issued after the new CDEC framework took effect in November, 2012, revealed that 15 submissions (65.2%) received a positive recommendation ("list with criteria/conditions") while 8 submissions (34.8)% received a negative recommendation ("do not list"). Reimbursement recommendations. The most frequent reason for a negative reimbursement recommendation was insufficient evidence to determine clinical effectiveness (5 \[62.5%\] submissions), followed by lack of clinical effectiveness (2 \[25.0%\] submissions), and multiple reasons (1 \[12.5%\] submission). No submission received a negative reimbursement recommendation due to cost alone.Fig. 7Listing reimbursement recommendations since 2004 Fig. 8Reasons for negative reimbursement recommendation since 2004

Discussion {#Sec4}
==========

Since its inception in 2004, the CADTH CDR has received a total of 63 DRD submissions (based on a definition of a rare disease being any disease with a prevalence of \<50 patients per 100,000). These 63 submissions have addressed 35 unique rare diseases, which represents a very small proportion of the approximately 7,000 rare diseases described to date \[[@CR9]\]. The number of DRD submissions received annually increased recently, from 1 to 5 submissions between 2004 and 2006 to 8 to 10 submissions between 2013 and 2015. Whether this reflects a general increase in the development of DRDs in unclear, although this would not be an unreasonable conclusion based on reports by others of increased focus of manufacturers on treatment for rare diseases \[[@CR1], [@CR10]\]. If the increase in the number of DRD submissions observed in our study continues, this suggests that HTA agencies such as the CADTH CDR will likely be required to review an increasingly large number of DRD submissions in future, which could pose some challenges given the unique clinical and economic complexities of these types of submission.

One of the greatest challenges in determining whether treatments for rare diseases are effective is the generation of sufficiently robust clinical data, because it is difficult to adequately power clinical studies due to a dearth of patients with the rare disease being studied. The difficulties encountered with recruiting adequate numbers of patients has led to the general perception that many aspects of conventional study designs are unfeasible in the study of DRDs. We expected to find mostly small size studies and single arm uncontrolled designs. However, 82.5% of the submissions with information on study design included at least one double-blinded RCT, and 71.4% of the submissions had enrolled more than 150 patients in their studies; this was despite most DRD submissions being for DRDs with a prevalence of \<10 patients per 100,000 people. Our findings provide evidence that the aforementioned perception may be incorrect in most cases, and instead, suggest that it is indeed possible to design and conduct high-quality clinical studies despite issues with patient recruitment.

The average annual treatment cost per patient for the DRD submissions made to the CADTH CDR was \$215,631, and almost half of the reported treatment costs were over \$200,000 annually. This average, however, was calculated from only approximately half of the submissions, as cost information was either not reported or was redacted from published reports. Cost information was not available in most cases due to confidential pricing. Although rare diseases affect small numbers of people on an individual basis, approximately 7,000 unique rare diseases have been described to date \[[@CR7]\], and as a whole, it is estimated that rare diseases affect 1 in 12 Canadians \[[@CR11]\]. Moreover, the pace of development of treatments for rare diseases has increased in recent years \[[@CR1], [@CR10]\], which might be reflected in the increased growth in the number of DRD submissions made to CDR over the last few years. The potential future implications on public financial health resources that could result from increased development and funding of high-cost DRDs will require the timely development of innovative regulatory, HTA, and reimbursement frameworks to mitigate issues such as high opportunity costs and to ensure access to effective DRDs.

Over half of all the DRD CDR submissions received a positive reimbursement recommendation. The 'do not list' reimbursement recommendation was mostly due to reasons related to either lack of clinical efficacy or lack of enough evidence to inform on clinical efficacy. Given that most studies have supplied high-quality design, the reason for a 'do not list' due to 'lack of clinical effectiveness' was largely concerned with a lack of clinically relevant outcomes. This can be a challenge in rare-disease research as the use of surrogate outcomes could prove more convenient, statistically and financially, than clinical outcomes. With the recent emphasis towards more engagement of patients, evaluation committees want to assess beyond the surrogate outcomes and need to know if tangible changes that will better patient's quality of life are considered in the research \[[@CR11]\]. Clinical outcomes, patient-reported outcomes with a minimally important clinical difference, and surrogate outcomes with established clinical associations are needed to address the insufficient evidence in some of the DRD CDR submissions.

A CDEC reimbursement recommendation is non-binding on the CDR-participating drug plans. Each of the drug plans subsequently makes its own decisions based on the CDEC recommendation in addition to other factors including the plan's mandate, jurisdictional priorities, pan-Canadian Pharmaceutical Alliance (pCPA) negotiations, and financial resources. Although we used a prevalence rate of \< 50 per 100,000 people as a definition of a rare disease for the purpose of this analysis, CADTH has no formal definition for DRDs. In March 2016, CADTH published an update to the CDEC framework \[[@CR12]\]. The framework provides guidance on the deliberation for drugs that may fulfill a significant unmet clinical need, and the rarity of the condition is only one of several factors that are considered to define a significant unmet clinical need.

While we have provided a comprehensive picture of the characteristics of DRD submissions to the CADTH CDR, our study is not without limitations. First, data extraction was conducted by one reviewer and verified by another, rather than in duplicate; while verification would ensure a high level of accuracy, it is not as accurate as a duplicate extraction. Second, our estimated prevalence values were in some cases derived from different sources and most were based on prevalence rates for populations in countries other than Canada; therefore, these values might not be an accurate representation of Canadian prevalence rates. In addition, we did not take into account the variability in prevalence among different locations; therefore, we might have included diseases that are not rare in all countries, while we might not have included diseases that are rare in some countries. This issue was further complicated by the fact that a challenge for the reviewers was whether to consider a drug that targets a small subpopulation of a common disease as a DRD. It was decided to keep the focus on drugs with a condition that is unique and rare versus a very small subpopulation of a relatively more common disease. Finally, the number of submissions that we identified was not sufficiently large to perform robust statistical analysis of associations among different characteristics.

Conclusions {#Sec5}
===========

The annual number of DRD submissions made to the CADTH CDR has approximately doubled increased since 2013 compared to previous years, reflecting growth in the development of treatments for rare diseases. Over the last decade, more than half of DRD submissions resulted in a positive CDEC reimbursement recommendation, while most submissions that received a negative recommendation were characterized by low-quality clinical evidence and/or a lack of supportive clinical evidence. Although the average cost of DRD treatments in submissions made to the CDR is high, high cost was not a reason for a negative reimbursement recommendation in any recommendation after October 2012.
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MCID

:   Minimal clinically important difference
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:   Pan-Canadian Oncology Drug Review
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